Entera Bio Ltd. Ordinary Shares (ENTX) Dividend History

Entera Bio Ltd. (ENTX) is a biopharmaceutical company focused on developing oral biologic therapies for serious medical conditions. Leveraging its proprietary platform, the company aims to deliver biologic drugs that can be administered orally, offering potential advantages over traditional injectable treatments. Entera Bio’s pipeline includes candidates targeting osteoporosis, hormone deficiencies, and other indications, with an emphasis on improving patient compliance and convenience.

Kiryat Hadassah, Minrav Building, Jerusalem, L3, 9112002
Phone: 972-2-532-7151
Website: https://www.enterabio.com

Dividend History

Entera Bio Ltd. Ordinary Shares currently does not pay dividends

Company News

  • OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

    OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the ENDO 2025 Annual Meeting.

    GlobeNewswire Inc.
    Featured Companies: OPK
  • AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

    AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

    Zacks Investment Research
    Featured Companies: ABBV ALXO ANVS
  • Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying

    The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Entera Bio The Trade: Entera Bio Ltd. (NASDAQ: ENTX) Director Haya Taitel acquired a total of 7,615 shares an average price of $0.77. To acquire these shares, it cost around $5,86. What’s Happening: Entera Bio announced that it received an extension of 180 calendar days from the Nasdaq stock market to regain compliance. What Entera Bio Does: Entera Bio Ltd is a clinical-stage biopharmaceutical ...

    Benzinga
    Featured Companies: OPK VGZ
Page data last updated 07/23/2025 21:00:18 UTC